TCRs with Distinct Specificity Profiles Use Different Binding Modes to Engage an Identical Peptide-HLA Complex.


Journal

Journal of immunology (Baltimore, Md. : 1950)
ISSN: 1550-6606
Titre abrégé: J Immunol
Pays: United States
ID NLM: 2985117R

Informations de publication

Date de publication:
01 04 2020
Historique:
received: 01 08 2019
accepted: 29 12 2019
pubmed: 28 2 2020
medline: 24 10 2020
entrez: 28 2 2020
Statut: ppublish

Résumé

The molecular rules driving TCR cross-reactivity are poorly understood and, consequently, it is unclear the extent to which TCRs targeting the same Ag recognize the same off-target peptides. We determined TCR-peptide-HLA crystal structures and, using a single-chain peptide-HLA phage library, we generated peptide specificity profiles for three newly identified human TCRs specific for the cancer testis Ag NY-ESO-1

Identifiants

pubmed: 32102902
pii: jimmunol.1900915
doi: 10.4049/jimmunol.1900915
pmc: PMC7086387
doi:

Substances chimiques

HLA-A2 Antigen 0
Histocompatibility Antigens 0
Peptide Library 0
Peptides 0
Receptors, Antigen, T-Cell 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1943-1953

Informations de copyright

Copyright © 2020 by The American Association of Immunologists, Inc.

Références

PLoS One. 2018 Oct 15;13(10):e0205491
pubmed: 30321203
Proc Natl Acad Sci U S A. 2008 Sep 30;105(39):15010-5
pubmed: 18809922
Acta Crystallogr D Biol Crystallogr. 2004 Dec;60(Pt 12 Pt 1):2126-32
pubmed: 15572765
Science. 1999 Oct 29;286(5441):958-61
pubmed: 10542151
Nat Protoc. 2016 Sep;11(9):1599-616
pubmed: 27490633
J Appl Crystallogr. 2007 Aug 1;40(Pt 4):658-674
pubmed: 19461840
Immunity. 2003 Jan;18(1):53-64
pubmed: 12530975
BMC Bioinformatics. 2019 Jan 5;20(1):7
pubmed: 30611210
Cancer Treat Rev. 2019 Jul;77:35-43
pubmed: 31207478
Acta Crystallogr D Biol Crystallogr. 2004 Dec;60(Pt 12 Pt 1):2256-68
pubmed: 15572779
Science. 2012 May 25;336(6084):1030-3
pubmed: 22628654
Nat Biotechnol. 2005 Mar;23(3):349-54
pubmed: 15723046
PLoS One. 2017 Oct 26;12(10):e0185056
pubmed: 29073143
Nucleic Acids Res. 2010 Jan;38(Database issue):D301-7
pubmed: 19900967
Annu Rev Immunol. 2015;33:169-200
pubmed: 25493333
Nat Med. 2012 Jun;18(6):980-7
pubmed: 22561687
Immunity. 2009 Dec 18;31(6):849-51
pubmed: 20064442
Immunity. 2009 Dec 18;31(6):897-908
pubmed: 20064448
Acta Crystallogr D Struct Biol. 2016 Apr;72(Pt 4):558-75
pubmed: 27050135
J Biol Chem. 2012 Jan 6;287(2):1168-77
pubmed: 22102287
Acta Crystallogr D Biol Crystallogr. 2006 Jan;62(Pt 1):72-82
pubmed: 16369096
Chem Biol. 2007 Aug;14(8):909-22
pubmed: 17719490
Sci Transl Med. 2013 Aug 7;5(197):197ra103
pubmed: 23926201
Nat Chem Biol. 2018 Oct;14(10):934-942
pubmed: 30224695
J Immunother. 2005 May-Jun;28(3):252-7
pubmed: 15838382
J Biol Chem. 2013 May 31;288(22):15442-54
pubmed: 23569211
J Biol Chem. 2004 May 28;279(22):23438-46
pubmed: 15004033
Nature. 1996 Nov 14;384(6605):134-41
pubmed: 8906788
Nat Commun. 2018 Mar 12;9(1):1026
pubmed: 29531227
Nat Immunol. 2016 Jan;17(1):87-94
pubmed: 26523866
Acta Crystallogr D Biol Crystallogr. 1997 May 1;53(Pt 3):240-55
pubmed: 15299926
Sci Rep. 2016 Jan 13;6:18851
pubmed: 26758806
Sci Rep. 2013 Nov 06;3:3097
pubmed: 24192765
J Clin Invest. 2016 Sep 1;126(9):3626
pubmed: 27525441
Nat Biotechnol. 2001 Jan;19(1):75-8
pubmed: 11135557
J Immunol. 2000 Jul 15;165(2):948-55
pubmed: 10878370
Nature. 2017 Jul 6;547(7661):94-98
pubmed: 28636589
Nucleic Acids Res. 2000 Jan 1;28(1):235-42
pubmed: 10592235
J Immunol. 2007 Nov 1;179(9):5845-54
pubmed: 17947658
J Immunol. 2017 Oct 1;199(7):2203-2213
pubmed: 28923982
Proc Natl Acad Sci U S A. 1992 Apr 15;89(8):3429-33
pubmed: 1565634
Protein Eng Des Sel. 2007 Aug;20(8):397-403
pubmed: 17644531
J Immunol. 2014 Mar 15;192(6):2885-91
pubmed: 24523505
Front Immunol. 2017 Aug 07;8:935
pubmed: 28824655
J Biol Chem. 2009 Oct 2;284(40):27281-9
pubmed: 19605354
Acta Crystallogr D Biol Crystallogr. 2010 Feb;66(Pt 2):133-44
pubmed: 20124693
Curr Top Med Chem. 2008;8(18):1555-72
pubmed: 19075767
Protein Eng. 2003 Sep;16(9):707-11
pubmed: 14560057
Cell. 2014 May 22;157(5):1073-87
pubmed: 24855945
Methods Mol Biol. 2015;1266:171-84
pubmed: 25560075
J Immunol. 2009 Jul 1;183(1):430-7
pubmed: 19542454
Acta Crystallogr D Biol Crystallogr. 2010 Feb;66(Pt 2):125-32
pubmed: 20124692
Immunity. 2011 Nov 23;35(5):681-93
pubmed: 22101157
Immunity. 1998 Apr;8(4):403-11
pubmed: 9586631
Sci Rep. 2016 Oct 13;6:35326
pubmed: 27734930
Nat Rev Immunol. 2006 Dec;6(12):883-94
pubmed: 17110956
Front Immunol. 2017 Oct 04;8:1210
pubmed: 29046675
Nat Methods. 2009 Nov;6(11):786-7
pubmed: 19876014
Nature. 2017 Jul 6;547(7661):89-93
pubmed: 28636592
Cell Rep. 2017 Apr 18;19(3):569-583
pubmed: 28423320
Annu Rev Immunol. 2006;24:419-66
pubmed: 16551255
J Exp Med. 2005 Apr 18;201(8):1243-55
pubmed: 15837811
J Immunol. 2011 Sep 1;187(5):2453-63
pubmed: 21795600

Auteurs

Charlotte H Coles (CH)

Immunocore, Ltd., Abingdon, Oxfordshire OX14 4RY, United Kingdom; and.

Rachel M Mulvaney (RM)

Immunocore, Ltd., Abingdon, Oxfordshire OX14 4RY, United Kingdom; and.

Sunir Malla (S)

Immunocore, Ltd., Abingdon, Oxfordshire OX14 4RY, United Kingdom; and.

Andrew Walker (A)

Immunocore, Ltd., Abingdon, Oxfordshire OX14 4RY, United Kingdom; and.

Kathrine J Smith (KJ)

GlaxoSmithKline, Medicines Research Centre, Stevenage, Hertfordshire SG1 2NY, United Kingdom.

Angharad Lloyd (A)

Immunocore, Ltd., Abingdon, Oxfordshire OX14 4RY, United Kingdom; and.

Kate L Lowe (KL)

Immunocore, Ltd., Abingdon, Oxfordshire OX14 4RY, United Kingdom; and.

Michelle L McCully (ML)

Immunocore, Ltd., Abingdon, Oxfordshire OX14 4RY, United Kingdom; and.

Ruth Martinez Hague (R)

Immunocore, Ltd., Abingdon, Oxfordshire OX14 4RY, United Kingdom; and.

Milos Aleksic (M)

Immunocore, Ltd., Abingdon, Oxfordshire OX14 4RY, United Kingdom; and.

Jane Harper (J)

Immunocore, Ltd., Abingdon, Oxfordshire OX14 4RY, United Kingdom; and.

Samantha J Paston (SJ)

Immunocore, Ltd., Abingdon, Oxfordshire OX14 4RY, United Kingdom; and.

Zoe Donnellan (Z)

Immunocore, Ltd., Abingdon, Oxfordshire OX14 4RY, United Kingdom; and.

Fiona Chester (F)

Immunocore, Ltd., Abingdon, Oxfordshire OX14 4RY, United Kingdom; and.

Katrin Wiederhold (K)

Immunocore, Ltd., Abingdon, Oxfordshire OX14 4RY, United Kingdom; and.

Ross A Robinson (RA)

Immunocore, Ltd., Abingdon, Oxfordshire OX14 4RY, United Kingdom; and.

Andrew Knox (A)

Immunocore, Ltd., Abingdon, Oxfordshire OX14 4RY, United Kingdom; and.

Andrea R Stacey (AR)

Immunocore, Ltd., Abingdon, Oxfordshire OX14 4RY, United Kingdom; and.

Joseph Dukes (J)

Immunocore, Ltd., Abingdon, Oxfordshire OX14 4RY, United Kingdom; and.

Emma Baston (E)

Immunocore, Ltd., Abingdon, Oxfordshire OX14 4RY, United Kingdom; and.

Sue Griffin (S)

GlaxoSmithKline, Medicines Research Centre, Stevenage, Hertfordshire SG1 2NY, United Kingdom.

Bent K Jakobsen (BK)

Immunocore, Ltd., Abingdon, Oxfordshire OX14 4RY, United Kingdom; and.

Annelise Vuidepot (A)

Immunocore, Ltd., Abingdon, Oxfordshire OX14 4RY, United Kingdom; and.

Stephen Harper (S)

Immunocore, Ltd., Abingdon, Oxfordshire OX14 4RY, United Kingdom; and Stephen.Harper@immunocore.com bent.jakobsen@immunocore.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH